Archive for December 2023
Neuroprotection after cardiac arrest with 2-iminobiotin
Admiraal M.M., Velseboer D.C., Tjabbes H., Vis P., Peeters-Scholte C., Horn J. Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics. Frontiers in Neurology 2023. [Link to publication ].
Read MoreAdvances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development
Goulooze S.C, Vis P., Krekels E.H.J., Knibbe C.A.J. Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses. Expert Review of Clinical Pharmacology 2023 [Link to publication].
Read MorePharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease
Eissing T., Goulooze S.C., Berg van der P., Noort van M., Ruppert M., Snelder N., Garmann D., Lippert J., Heinig R., Brinker M., Heerspink H.J.L. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes, Obesity and Metabolism 2023 [Link to publication].
Read More